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Introduction {#jdi12087-sec-0005}
============

The *Dementia UK* report predicts that 34 million people worldwide will have dementia by 2050, and 71% of these people will live in developing countries[1](#jdi12087-bib-0001){ref-type="ref"}. Currently, nearly 18 million people have dementia worldwide[1](#jdi12087-bib-0001){ref-type="ref"}. The diagnosis of dementia and especially Alzheimer\'s disease (AD) is usually retrospective, based on clinical phenomenology and exclusion of other medical problems[2](#jdi12087-bib-0002){ref-type="ref"}. The current management of dementia targets symptoms only and not the disease course[2](#jdi12087-bib-0002){ref-type="ref"}. In view of the emergence of risk factors playing key roles in the disease pathology of AD, such as age, obesity, diabetes mellitus, stroke and apolipoprotein ε4 (APOE ε4), it has become important to generate stronger evidence to strengthen the role of such risk factors, and aim to prevent such risk factors.

Diabetes mellitus is associated with changes in cognition[3](#jdi12087-bib-0003){ref-type="ref"}. A number of *in vivo* studies postulate a correlation between the mechanism of insulin resistance, and the pathogenesis of plaque formation and impaired neuronal signalling in AD[4](#jdi12087-bib-0004){ref-type="ref"}. Several longitudinal epidemiological studies over the past two decades have linked diabetes mellitus, particularly type 2 diabetes mellitus, with an increased risk of cognitive impairment and dementia. If these studies have correctly predicted the association, then the future burden of dementia might be even greater than that estimated as the prevalence of diabetes mellitus continues to rise[5](#jdi12087-bib-0005){ref-type="ref"}. Early data that linked diabetes mellitus with cognitive impairment came from cross‐sectional studies of poor methodological quality[6](#jdi12087-bib-0006){ref-type="ref"}. A recent meta‐analysis on a similar topic was carried out, and concluded that there is an association between diabetes and dementia[3](#jdi12087-bib-0003){ref-type="ref"}. The studies assessing the link between type 2 diabetes mellitus and all type dementia (ATD; includes AD, vascular dementia \[VaD\] and dementia of other etiologies)[7](#jdi12087-bib-0007 jdi12087-bib-0008 jdi12087-bib-0009 jdi12087-bib-0010 jdi12087-bib-0011 jdi12087-bib-0012 jdi12087-bib-0013 jdi12087-bib-0014 jdi12087-bib-0015 jdi12087-bib-0016 jdi12087-bib-0017 jdi12087-bib-0018 jdi12087-bib-0019 jdi12087-bib-0020 jdi12087-bib-0021 jdi12087-bib-0022 jdi12087-bib-0023 jdi12087-bib-0024 jdi12087-bib-0025 jdi12087-bib-0026){ref-type="ref"}, AD[7](#jdi12087-bib-0007 jdi12087-bib-0008 jdi12087-bib-0009 jdi12087-bib-0010 jdi12087-bib-0011 jdi12087-bib-0014 jdi12087-bib-0015 jdi12087-bib-0016 jdi12087-bib-0019 jdi12087-bib-0020 jdi12087-bib-0021 jdi12087-bib-0023 jdi12087-bib-0024 jdi12087-bib-0025 jdi12087-bib-0027 jdi12087-bib-0028 jdi12087-bib-0029 jdi12087-bib-0030 jdi12087-bib-0031 jdi12087-bib-0032){ref-type="ref"} and VaD[9](#jdi12087-bib-0009 jdi12087-bib-0010 jdi12087-bib-0011 jdi12087-bib-0014 jdi12087-bib-0015 jdi12087-bib-0016 jdi12087-bib-0019 jdi12087-bib-0020 jdi12087-bib-0021 jdi12087-bib-0023 jdi12087-bib-0024 jdi12087-bib-0033 jdi12087-bib-0034){ref-type="ref"} have given conflicting results. Some epidemiological studies have reported that diabetes is independently implicated in the development of dementia[26](#jdi12087-bib-0026){ref-type="ref"}. However, these findings are inconsistent for its subtypes. Some studies have found an association between diabetes and both AD and VaD[9](#jdi12087-bib-0009 jdi12087-bib-0033){ref-type="ref"}, whereas others found an association with either only VaD[11](#jdi12087-bib-0011){ref-type="ref"} or AD[15](#jdi12087-bib-0015 jdi12087-bib-0016){ref-type="ref"}. The risk quantification is available only for AD[2](#jdi12087-bib-0002){ref-type="ref"}, but not for ATD and VaD. There has been no consensus in regards to the incidence of ATD, AD and VaD in diabetes mellitus as compared with the general population. In the present pooled meta‐analysis of published prospective studies, we aim to investigate whether diabetes mellitus increases the risk of dementia, and whether diabetes is differentially related to the main subtypes of dementia, that is AD and VaD.

Materials and Methods {#jdi12087-sec-0006}
=====================

Literature Search {#jdi12087-sec-0007}
-----------------

A comprehensive literature search was carried out using PubMed, EMBASE and other databases (up to January 2012) for observational cohort studies investigating an association between diabetes and ATD, AD and VaD using keywords dementia or Alzheimer\'s or cognition or vascular dementia and diabetes or diabetes mellitus. We searched for additional studies in bibliographies and citation sections of retrieved articles.

The present study was reported in accordance with the Meta‐analysis of Observational Studies in Epidemiology guidelines for meta‐analysis of observational studies.

Study Selection {#jdi12087-sec-0008}
---------------

Two members (GK and FS) of the study group independently reviewed the titles and abstracts of all identified citations as per the inclusion criteria. An abstract was judged relevant if it reported original data, was published in English, was from epidemiological studies (cohort studies only), the outcome variable was ATD, AD and VaD, and the predictor variable was diabetes (both type 1 and 2 diabetes). Cohort studies reporting risk ratios (RR) or hazard ratios (HR) with 95% confidence interval (CI) were included in the meta‐analysis. The manuscripts were excluded if the exposure was not diabetes; the outcome was not incidence of dementia, AD or VaD; if the study participants were cognitively impaired during baseline assessment; if no effect estimates were reported; or if not enough raw data was reported for a RR value to be calculated. We also excluded case--control and cross‐sectional studies, as the age of onset of one or both of the diseases are often unknown. In such cases, only the comorbidities are described. Thus, in order to draw inferences about diabetes as a risk factor for developing dementia, longitudinal information (prospective follow up) about age at disease onset is critical. If a manuscript included data on risk factors other than diabetes, we extracted the data on diabetes only. Any discrepancies were resolved by consensus in‐group conference. When there were multiple publications for the same population, we included the data from which ever study reported detailed and updated data.

The diagnostic criteria applied were similar across studies, which is probably because of the narrow time frame (1997--2012). Any dementia was generally defined according to the criteria from the Diagnostic and Statistical Manual of Mental Disorders, third edition (DSM‐III) or the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM‐IV)[35](#jdi12087-bib-0035){ref-type="ref"}. AD was diagnosed according to the National Institute of Neurological and Communicative Diseases and Stroke, and the Alzheimer\'s Disease and Related Disorders Association (NINCDS‐ADRDA) criteria[36](#jdi12087-bib-0036){ref-type="ref"}, including both cases of probable and possible AD. VaD was mostly diagnosed according to the National Institute of Neurological Disorders and Stroke, and the Association Internationale pour la Recherche et L\'Enseignement en Neurosciences criteria[37](#jdi12087-bib-0037){ref-type="ref"}, including both probable and possible cases.

Data Extraction and Quality Assessment {#jdi12087-sec-0009}
--------------------------------------

The following data were extracted from each study: author; study location; date the study was carried out; date of publication; journal; title; number and age of participants; study design; inclusion and exclusion criteria; and methods of diagnosis of diabetes, dementia, AD and VaD. For all included studies, we extracted the source cohort, follow‐up period, RR or HR with 95% CI, and confounders adjusted for in the statistical analysis.

Two reviewers (GK and AB) assessed the quality of each selected study using the Newcastle Ottawa Scale (NOS)[38](#jdi12087-bib-0038){ref-type="ref"}. We defined studies of high quality as those that scored the maximum nine stars on the NOS; studies of medium quality scored seven or eight stars. Any discrepancy in quality assessment was discussed and resolved by the two reviewers.

Data Synthesis and Statistical Analysis {#jdi12087-sec-0010}
---------------------------------------

The primary outcome measure was to calculate the RR of dementia, AD and VaD individually. To assess the differential effect of diabetes on risk of AD and VaD, separate analysis was carried out for each category of dementia. To assess the significance of pooled effect estimate, we used a *Z*‐test; a *P*‐value \<0.10 was considered to be statistically significant. To assess heterogeneity among studies, we used the Cochran *Q* and *I*^2^ statistics; for the *Q* statistic, a *P*‐value \<0.10 was considered statistically significant for heterogeneity; for *I*^2^, a value \>50% was considered as a measure of severe heterogeneity. If heterogeneity was present, risk ratios were pooled using a random effects model (DerSimonian and Laird method[39](#jdi12087-bib-0039){ref-type="ref"}), otherwise a fixed effects model (Hedges‐Olkin method[39](#jdi12087-bib-0039){ref-type="ref"}) was used.

Prespecified subgroup analysis was carried out to assess the source of heterogeneity, according to: (i) quality of study by NOS; (ii) follow‐up period (\<6 and \>6 years); (iii) adjustment for body mass index (BMI); (iv) adjustment for cardiovascular risk factors; and (v) adjustment for APOE ε4 allele. Tests for interaction using summary estimates were carried out using the method described by Altman and Bland[39](#jdi12087-bib-0039){ref-type="ref"}. To assess the robustness of the association, we also carried out sensitivity analysis by excluding the outliers. The publication bias was assessed using both funnel plot and Begg\'s test. If a publication bias in the pooled estimate was identified, we applied the Trim and Fill method[39](#jdi12087-bib-0039){ref-type="ref"}, which negotiates the lack of studies on a particular side of the funnel. When data were not uniformly reported to allow formal statistical analysis, we presented the data in a narrative format. All statistical tests were two‐sided, and *P* \< 0.05 was considered statistically significant, except where otherwise specified. Data were analyzed using STATA version 11.0 (StataCorp, College Station, TX, USA).

Results {#jdi12087-sec-0011}
=======

Search Results {#jdi12087-sec-0012}
--------------

A total of 67,083 citations were identified during the initial search (Figure [1](#jdi12087-fig-0001){ref-type="fig"}). After reviewing the citations, 67,033 citations were considered ineligible as they were reviews, editorials, case reports and so on, and did not met the inclusion criteria. After reviewing the reference list of the remaining 50 studies, three more studies were considered. After detailed evaluation of 53 potential manuscripts, 25 manuscripts were excluded for reasons shown in Figure [1](#jdi12087-fig-0001){ref-type="fig"}.

![Flow chart showing the number of citations retrieved by individual searches and the number of studies included in review. RR, risk ratio.](jdi-4-640-g1){#jdi12087-fig-0001}

Study Characteristics {#jdi12087-sec-0013}
---------------------

We identified 28 manuscripts reporting data on diabetes mellitus and the risk of one or more types of dementia in patients with diabetes as compared with non‐diabetes patients published between 1997 and 2011. Among these, 20 studies reported the risk of ATD, 20 reported the risk of AD and 13 reported the risk of VaD. The present meta‐analysis includes 1,148,041 participants, of whom 89,708 participants were having diabetes and 1,058,333 were non‐diabetics. Participants were followed up for 2--30 years, reporting a total of more than 15,039 incident cases of ATD, 4592 AD and 1002 VaD. Information on source population, method of ascertainment of exposure, diagnosis of dementia and adjustment for confounders is presented in Table [1](#jdi12087-tbl-0001){ref-type="table-wrap"}.

###### Descriptive characteristics of the studies included in the analysis

  Author (year of publication)                                 Study site    Study name                                                            Age at baseline (years)   Follow up (years)/start‐end year   Total population/with diabetes (*n*)   With dementia (*n*)   With Alzheimer\'s disease (*n*)   With vascular dementia (n)   QR
  ------------------------------------------------------------ ------------- --------------------------------------------------------------------- ------------------------- ---------------------------------- -------------------------------------- --------------------- --------------------------------- ---------------------------- --------
  Leibson (1997)[7](#jdi12087-bib-0007){ref-type="ref"}        USA           NR                                                                    ≥45                       15 (1970--1984)                    1,455/1,455                            101                   77                                NR                           Medium
  Ott (1999)[8](#jdi12087-bib-0008){ref-type="ref"}            Netherlands   The Rotterdam study                                                   ≥55                       2.1 (1991--1994)                   6,370/692                              126                   89                                NR                           High
  Tyas (2001)[27](#jdi12087-bib-0027){ref-type="ref"}          USA           Manitoba Study of Health and Aging                                    ≥65                       5 (1991--1996)                     694/44                                 NR                    36                                NR                           High
  Posner (2002)[33](#jdi12087-bib-0033){ref-type="ref"}        USA           Washington Heights‐Inwood Columbia Aging Project                      ≥65                       7 (1991--1998)                     1,259/NR                               NR                    157                               56                           Medium
  MacKnight (2002)[9](#jdi12087-bib-0009){ref-type="ref"}      Canada        Canadian Study of Health and Aging                                    ≥65                       5 (1991--1996)                     5,574/503                              NR                    267                               NR                           High
  Peila (2002)[10](#jdi12087-bib-0010){ref-type="ref"}         USA           The Honolulu‐Asia Aging Study                                         ≥65                       2.9 (NR)                           2,574/900                              76                    68                                33                           High
  Hassing (2002)[11](#jdi12087-bib-0011){ref-type="ref"}       Sweden        Origins of Variance in the Old‐Old                                    ≥80                       9 (1991--1999)                     702/108                                187                   105                               50                           High
  Honig (2003)[28](#jdi12087-bib-0028){ref-type="ref"}         USA           Washington Heights‐Inwood Columbia Aging Project                      ≥65                       7 (1991--1998)                     1,766/NR                               NR                    181                               NR                           Medium
  Beeri (2004)[12](#jdi12087-bib-0012){ref-type="ref"}         Israel        Israeli Ischemic Heart Disease study                                  40--65                    \> 30 (1965--1999)                 1,892/867                              309                   NR                                NR                           Medium
  Arvanitakis (2004)[29](#jdi12087-bib-0029){ref-type="ref"}   USA           Religious Orders Study                                                ≥55                       5.5 (1994--2003)                   824/127                                                      151                               NR                           High
  Whitmer (2005)[13](#jdi12087-bib-0013){ref-type="ref"}       USA           Kaiser Permanente Medical Care Program                                40--44                    9 (1994--2003)                     8,845/1,004                            721                   NR                                NR                           High
  Borenstein (2005)[30](#jdi12087-bib-0030){ref-type="ref"}    USA           Kame Project                                                          ≥65                       9 (1992--2001)                     1,859/NR                               NR                    90                                NR                           Medium
  Hayden (2006)[14](#jdi12087-bib-0014){ref-type="ref"}        USA           The Cache County Study                                                ≥65                       3.2 (1995--1999)                   3,264/322                              185                   104                               37                           High
  Akomolafe (2006)[15](#jdi12087-bib-0015){ref-type="ref"}     USA           Framingham Study                                                      70 mean age               12.7 (1977--1990)                  2,210/202                              319                   237                               32                           High
  Lin (2006)[34](#jdi12087-bib-0034){ref-type="ref"}           Taiwan        NR                                                                    NR                        2 (2003--2005)                     345/93                                 NR                    NR                                155                          Medium
  Irie (2008)[16](#jdi12087-bib-0016){ref-type="ref"}          USA           The Cardiovascular Health Study Cognition Study                       NR                        5.4 (1992--1999)                   2,547/320                              411                   207                               58                           High
  Peters (2009)[17](#jdi12087-bib-0017){ref-type="ref"}        UK            Hypertension in the Very Elderly Trial                                ≥80                       2 (NR)                             3,336/518                              263                   NR                                NR                           Medium
  Alonso (2009)[18](#jdi12087-bib-0018){ref-type="ref"}        USA           Atherosclerosis Risk in Communities study                             45--64                    13 (1991--2004)                    11,151/1,444                           203                   NR                                NR                           High
  Raffatin (2009)[19](#jdi12087-bib-0019){ref-type="ref"}      France        The Three‐City study                                                  ≥65                       4 (1999--2004)                     7,087/539                              208                   134                               40                           High
  Toro (2009)[31](#jdi12087-bib-0031){ref-type="ref"}          Germany       Interdisciplinary Longitudinal Study on Adult Development and Aging   75                        NR                                 381/77                                 NR                    26                                NR                           Medium
  Xu (2009)[20](#jdi12087-bib-0020){ref-type="ref"}            Sweden        Kungsholmen project                                                   ≥75                       9 (1988--1997)                     1,248/75                               420                   320                               47                           High
  Ahtiluoto (2010)[21](#jdi12087-bib-0021){ref-type="ref"}     Finland       Vantaa85 + Study                                                      ≥85                       9 (1991--2001)                     NR/NR                                  106                   NR                                NR                           High
  Hsu (2011)[22](#jdi12087-bib-0022){ref-type="ref"}           Taiwan        NR                                                                    ≥50                       7 (2000--2007)                     229,025/29,748                         7835                  NR                                NR                           High
  Ohara (2011)[23](#jdi12087-bib-0023){ref-type="ref"}         Japan         The Hisayama Study                                                    ≥60                       15 (1988--2003)                    1,017/150                              156                   71                                39                           High
  Kimm (2011)[24](#jdi12087-bib-0024){ref-type="ref"}          Korea         NR                                                                    40--95                    14 (1993--2006)                    848,505/51,611                         3252                  1851                              610                          High
  Cheng (2011)[25](#jdi12087-bib-0025){ref-type="ref"}         USA           Columbia Aging Project                                                ≥65                       9 (1999--2007)                     1,488/253                              161                   149                               NR                           Medium
  Creavin (2011)[26](#jdi12087-bib-0026){ref-type="ref"}       UK            Caerphilly Prospective Study                                          45--59                    10 (1983--1993)                    2,512/NR                               NR                    NR                                NR                           High
  Li (2011)[32](#jdi12087-bib-0032){ref-type="ref"}            China         NR                                                                    ≥55                       5 (2004--09)                       837/136                                NR                    298                               NR                           High

NR, not reported; QR, quality rating.

John Wiley & Sons, Ltd

Most of the studies used standard methods NINCDS[36](#jdi12087-bib-0036){ref-type="ref"} to diagnose various types of dementia; however, some studies have used ad‐hoc criteria[14](#jdi12087-bib-0014 jdi12087-bib-0015 jdi12087-bib-0016 jdi12087-bib-0019){ref-type="ref"} or were registry based[13](#jdi12087-bib-0013 jdi12087-bib-0018 jdi12087-bib-0020 jdi12087-bib-0024){ref-type="ref"}. Most of the studies assessed diabetes based on self‐report[13](#jdi12087-bib-0013 jdi12087-bib-0014 jdi12087-bib-0030){ref-type="ref"}, registry based[24](#jdi12087-bib-0024 jdi12087-bib-0032){ref-type="ref"} and antidiabetic medication usage[22](#jdi12087-bib-0022){ref-type="ref"}.

Main Analyses and Subgroup Analyses {#jdi12087-sec-0014}
-----------------------------------

### All Type Dementia {#jdi12087-sec-0015}

As significant heterogeneity was found between studies (*P*~*heterogeneity*~* *\< 0.01, *I*^2^ = 71.2%), a random‐effects model was chosen over a fixed‐effect model (Table [2](#jdi12087-tbl-0002){ref-type="table-wrap"}). Patients with diabetes were found to be at a significantly higher risk of ATD compared with the non‐diabetic population (pooled RR 1.73 (95% CI 1.65--1.82, *P *≤ 0.001). The multivariable‐adjusted RR of dementia for each study and all studies combined are shown in Figure [2](#jdi12087-fig-0002){ref-type="fig"}. Visual examination of the funnel plot showed minimal asymmetry, further confirmed by Egger\'s test (*P *= 0.83), indicating little or no publication bias in our analysis. Sensitivity analyses showed robustness of pooled RR, as RR values lay within the range of 1.57--1.63, thus clearly showing no major impact of any single study on pooled RR. Table [3](#jdi12087-tbl-0003){ref-type="table-wrap"} presents the results of subgroup analyses stratified by quality rating and adjustment for risk factors. There was no statistically significant difference observed among studies reporting the incidence of ATD subgrouped on the basis of follow up (*P*~*interaction*~ = 0.13), adjustment for BMI (*P*~*interaction*~ = 0.49), cardiovascular disease (*P*~*interaction*~ = 0.84) and APOE ε4 allele (*P*~*interaction*~ = 0.16). When studies were analyzed according to study quality assessed using NOS, high‐quality studies reported a stronger association (pooled RR 1.61, 95% CI 1.43--1.81, *P* ≤ 0.001) as compared with medium quality studies (pooled RR 1.54, 95% CI 1.10--2.15, *P* ≤ 0.001). We did not find a significant difference (*P*~*interaction*~ = 0.80) in the two pooled RR, as the studies were grouped according to the study quality.

###### Pooled risk ratios of all type dementia, Alzheimer\'s disease and vascular dementia

  Type of dementia       No. studies pooled   Pooled estimate   Level of significance of pooled RR   Tests of heterogeneity   Tests of publication bias                    
  ---------------------- -------------------- ----------------- ------------------------------------ ------------------------ --------------------------- -------- ------- ------
  All type dementia      20                   1.73              1.65--1.82                           \<0.001                  76.5 (22)                   \<0.01   71.25   0.12
  Alzheimer\'s disease   20                   1.56              1.41--1.73                           \<0.001                  23.3 (21)                   0.32     9.8     0.93
  Vascular dementia      13                   2.27              1.94--2.66                           \<0.001                  12.0 (12)                   0.52     0       0.41

CI, confidence interval; d.f., degrees of freedom; RR, relative risk.

John Wiley & Sons, Ltd

###### Overall risk ratios between diabetes and all type dementia, Alzheimer\'s disease and vascular dementia according to study characteristics

  Subgroup                      All type dementia   Alzheimer\'s disease                                       Vascular dementia                                                            
  ----------------------------- ------------------- ---------------------------------------------------------- ------------------- ---- ------------------- ------ ---- ------------------- ------
  Quality rating                                                                                                                                                                            
  High                          16                  1.61 (1.43--1.81)                                          0.80                15   1.48 (1.33--1.64)   0.43   11   2.19 (1.86--2.58)   0.48
  Medium                        4                   1.54 (1.10--2.15)                                                              5    1.62 (1.33--1.99)          2    3.2 (1.1--9.2)      
  Follow‐up period (years)                                                                                                                                                                  
  \<6                           7                   1.43 (1.23--1.66)                                          0.13                10   1.57 (1.33--1.87)   0.78   5    1.95 (1.39--2.75)   0.41
  ≥6                            13                  1.66 (1.46--1.89)[a](#jdi12087-note-0004){ref-type="fn"}                       10   1.52 (1.29--1.78)          8    2.29 (1.91--2.75)   
  Adjustments for confounders                                                                                                                                                               
   Body mass index                                                                                                                                                                          
  Yes                           7                   1.53 (1.33--1.77)                                          0.49                4    1.52 (1.21--1.91)   0.95   6    1.82 (1.26--2.62)   0.25
  No                            13                  1.64 (1.43--1.88)[a](#jdi12087-note-0004){ref-type="fn"}                       16   1.51 (1.36--1.67)          7    2.31 (1.93--2.77)   
   Cardiovascular diseases                                                                                                                                                                  
  Yes                           11                  1.61 (1.35--1.91)[a](#jdi12087-note-0004){ref-type="fn"}   0.84                7    1.46 (1.21--1.75)   0.50   7    1.88 (1.38--2.55)   0.22
  No                            9                   1.58 (1.45--1.71)                                                              13   1.57 (1.40--1.75)          6    2.35 (1.94--2.80)   
   APOE gene                                                                                                                                                                                
  Yes                           8                   1.79 (1.52--2.12)                                          0.16                4    1.57 (1.27--1.95)   0.83   4    2.36 (1.57--3.57)   0.72
  No                            12                  1.54 (1.35--1.75)[a](#jdi12087-note-0004){ref-type="fn"}                       16   1.53 (1.38--1.72)          9    2.18 (1.83--2.60)   

*P* \< 0.05.

Heterogeneity present (*I*^2^ \> 50%).

APOE, apolipoprotein; BMI, body mass index.

John Wiley & Sons, Ltd

![Diabetes and risk of all type dementia. CI, confidence interval.](jdi-4-640-g2){#jdi12087-fig-0002}

### Alzheimer\'s Disease {#jdi12087-sec-0016}

Because no significant heterogeneity (*P*~*heterogeneity*~* *= 0.30, *I*^2^ = 9.8%) was found, the fixed‐effects model was chosen over a random‐effects model (Table [2](#jdi12087-tbl-0002){ref-type="table-wrap"}). The pooled result of 20 studies showed that diabetes was found to be associated with a significantly higher risk of AD compared with non‐diabetic population (pooled RR 1.56, 95% CI 1.41--1.73, *P* = 0.00). The multivariable‐adjusted RRs of AD for each study and all studies combined are shown in Figure [3](#jdi12087-fig-0003){ref-type="fig"}. Visual examination of the funnel plot revealed minimal asymmetry, further confirmed by Egger\'s test (*P *= 0.93), indicating little or no publication bias in our analysis. Sensitivity analysis showed robustness of pooled RR and that RR values lay within the range of 1.54--1.59, and this clearly showed that no single study had a major impact on pooled RR. We did not find a significant difference (*P*~*interaction*~ = 0.43) in the two pooled RR, as the studies were grouped according to quality assessment (Table [3](#jdi12087-tbl-0003){ref-type="table-wrap"}).

![Diabetes and risk of Alzheimer\'s disease. CI, confidence interval.](jdi-4-640-g3){#jdi12087-fig-0003}

### Vascular Dementia {#jdi12087-sec-0017}

As we found no significant heterogeneity (*P*~*heterogeneity*~* *= 0.61, *I*^2^ = 0%), a fixed‐effects model was chosen over a random‐effects model (Table [2](#jdi12087-tbl-0002){ref-type="table-wrap"}). The pooled result of 13 studies showed that diabetes was associated with a significantly higher risk of VaD compared with the non‐diabetic population (pooled RR 2.27 \[95% CI 1.94--2.66\]). The multivariable‐adjusted RRs of VaD for each study and all studies combined are shown in Figure [4](#jdi12087-fig-0004){ref-type="fig"}. Visual examination of the funnel plot showed minimal asymmetry, further confirmed by Egger\'s test (*P *= 0.41), indicating little or no publication bias in our analysis. Sensitivity analyses showed robustness of pooled RR and that RR values lie within the range of 2.0--2.3, and this clearly showed that no single study had a major impact on pooled RR. We did not find a significant difference (*P*~*interaction*~ = 0.48) in the two pooled RR, as the studies were grouped according to the quality assessment (Table [3](#jdi12087-tbl-0003){ref-type="table-wrap"}).

![Diabetes and risk of vascular dementia. CI, confidence interval.](jdi-4-640-g4){#jdi12087-fig-0004}

Discussion {#jdi12087-sec-0018}
==========

The present meta‐analysis of 28 observational studies showed a 73% increased risk of ATD, 56% increase in AD and 127% increase in VaD in patients with history of diabetes as compared with non‐diabetic people. Some biological mechanisms have been postulated through which diabetes might increase the risk of AD[4](#jdi12087-bib-0004 jdi12087-bib-0010){ref-type="ref"}; vascular mechanisms, toxic effects of hyperglycemia, insulin resistance of the brain, formation of advanced glycation end‐products (AGE) and competition for insulin‐degrading enzyme (IDE) resulting in reduced degradation of β amyloid, but none of these have been proven unequivocally. As diabetes is known to increase the risk of cerebrovascular disease, its association with VaD is understandable[40](#jdi12087-bib-0040){ref-type="ref"}. Hyperglycemia in diabetes is usually associated with accelerated AGE formation. The mechanism behind the increased risk of AD might possibly be due to the fact that AGE‐mediated cross‐linking of extracellular proteins accelerates amyloid‐β aggregation[41](#jdi12087-bib-0041){ref-type="ref"}. AGEs might also be involved in microtubule associated tau protein stabilization and tangle formation. AGE‐related modifications might also contribute by decreasing protein solubility and increased protease resistance of several proteins involved in pathological lesions associated with AD[42](#jdi12087-bib-0042){ref-type="ref"}.

Advanced glycation end‐products and APOE ε4 allele has been found colocalized in senile plaques, and neurofibrillary tangles of patients with AD and other types of dementia[43](#jdi12087-bib-0043){ref-type="ref"}. The APOE ε4 allele has a reduced ability to repair neuronal damage and a decreased anti‐oxidant activity[44](#jdi12087-bib-0044){ref-type="ref"}, and promotes stabilization of β‐amyloid deposits[45](#jdi12087-bib-0045){ref-type="ref"}. The APOE ε4 allele also stimulates Aβ deposition and accelerates conversion of Aβ protein to insoluble deposits in the brain by binding to it[46](#jdi12087-bib-0046){ref-type="ref"}. Peila *et al*.[10](#jdi12087-bib-0010){ref-type="ref"} have also reported a high association (a fivefold increase) between AD and diabetes, particularly among carriers of the APOE ε4 allele.

Regarding the genetic predisposition, an association between the APOE ε4 allele and dementia is well known[24](#jdi12087-bib-0024){ref-type="ref"}. It has been reported that APOE ε4 allele carriers have an increased incidence of AD[21](#jdi12087-bib-0021){ref-type="ref"}. In several observational studies, it has been reported that the presence of the APOE ε4 allele in diabetic patients synergistically increased the incidence of AD and other types of dementia as compared with non‐diabetic patients[10](#jdi12087-bib-0010 jdi12087-bib-0016 jdi12087-bib-0021){ref-type="ref"}.

The other postulated mechanism is that in the brain, insulin is involved in various cognitive functions. A large number of insulin receptors are located in the hippocampus and cerebral cortex, which play a central role in memory. Insulin induces the release of β‐amyloid peptide (Ab) to the cell exterior, and also promotes the expression of IDE. IDE is also involved in the degradation of Ab. Thus, a lack of insulin will promote Ab accumulation[47](#jdi12087-bib-0047 jdi12087-bib-0048 jdi12087-bib-0049){ref-type="ref"}.

In the case of hyperinsulinemia or insulin‐resistance, as a result of downregulation, there is a fall in insulin receptors and less entry of insulin into the brain. Also, in the hyperinsulinemic state, the amount of IDE falls due to its higher consumption, resulting in an increase in Ab causing accelerated cognitive impairment. In this regard, a cohort study on middle‐aged adults reported an association between hyperinsulinemia and cognitive decline[50](#jdi12087-bib-0050){ref-type="ref"}. Also, in the Hisayama study, autopsy findings showed that hyperinsulinemia and hyperglycemia enhanced neuritic plaque formation[51](#jdi12087-bib-0051){ref-type="ref"}. Furthermore, Ronnemaa *et al*.[52](#jdi12087-bib-0052){ref-type="ref"} reported that a reduction in insulin secretion was associated with the onset of AD. Thus, insulin seems to be definitely connected with the AD pathology and insulin resistance to be associated with VaD through atherosclerosis.

In the present analysis also, we have found that diabetes causes an increased risk of both AD 1.56 (95% CI 1.41--1.73) and VaD 2.27 (95% CI 1.94--2.66). Differentiation between the underlying pathology of these two categories of dementia with diabetes is not very well elucidated.

The present findings are consistent with two previous systematic reviews assessing the risk of ATD in patients with type 2 diabetes mellitus[47](#jdi12087-bib-0047 jdi12087-bib-0053){ref-type="ref"}. Seven out of 10 studies by Biessels *et al*.[47](#jdi12087-bib-0047){ref-type="ref"} and five out of nine studies by Kloppenborg *et al*.[53](#jdi12087-bib-0053){ref-type="ref"} reported a higher risk of dementia in patients with diabetes. The present pooled analysis quantifies the data from 20 cohort studies, including 15,039 incident dementia cases reporting a strong association between ATD and its subtypes and diabetes (1.73 \[95% CI 1.65--1.82\]).

The possible reasons for variation in the results could arise from methodological differences; for example, different criteria of diagnosis and categorization of dementia[26](#jdi12087-bib-0026 jdi12087-bib-0029 jdi12087-bib-0032){ref-type="ref"}, varying diagnostic criteria of diabetes through different times[54](#jdi12087-bib-0054 jdi12087-bib-0055){ref-type="ref"}, different follow‐up times[14](#jdi12087-bib-0014 jdi12087-bib-0017 jdi12087-bib-0023){ref-type="ref"}, sample sizes[11](#jdi12087-bib-0011 jdi12087-bib-0022 jdi12087-bib-0024){ref-type="ref"}, specific populations[17](#jdi12087-bib-0017 jdi12087-bib-0021 jdi12087-bib-0025){ref-type="ref"} and so on. The most important factor is the cut‐off value of fasting plasma glucose for the diagnosis of diabetes. In the Prospective Study of Pravastatin in the Elderly at Risk and the Rotterdam study, although a decline in cognitive function was observed in diabetic patients as compared with non‐diabetic subjects, no significant association was noted between fasting blood glucose levels and cognitive impairment in non‐diabetics[56](#jdi12087-bib-0056){ref-type="ref"}.

Thus, it has been argued that there is a certain threshold above which abnormal blood glucose levels cause cognitive impairment or the involvement of factors other than hyperglycemia is greater in diabetic patients[57](#jdi12087-bib-0057){ref-type="ref"}. Diabetes treatment that minimizes dementia will be of growing importance, although the place of insulin is still controversial[8](#jdi12087-bib-0008){ref-type="ref"}.

The current meta‐analysis presents with a few strengths. As the present analysis was carried out on prospective studies, our findings are unlikely to be biased by recall bias and selection bias. We included 28 studies, with a total of 89,708 diabetes patients, which further strengthens our results. We also carried out sensitivity analysis to investigate whether any particular study explained the results, and the overall findings were robust. These are important determinants of the increased risk of dementia in people with diabetes, and likely to help in understanding the factors that are associated in diabetes patients, which can then be better regulated.

The study also had some limitations. Many, but not all, of the studies were adjusted for potential confounding factors, such as age and sex. Most studies did not assess a premorbid intelligence quotient in their study populations, but did adjust the RR for the possible effects of education. We also did not search for unpublished studies, and excluded studies published in languages other than English. This might also have influenced the results.

To summarize, the present meta‐analysis suggests that patients with diabetes are at higher risk of ATD. Further studies should report more detailed results, including those for subtypes of antidiabetic medications usage, along with the class of drugs, and the results should also be stratified by other risk factors in order to rule out residual confounding. Further assessment of the impact of measurement errors on the risk estimates is also warranted. Future studies are required to determine the role of good glycemic control among diabetes patients in lowering the risk of dementia.
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